Triflusal

CAS No. 322-79-2

Triflusal( Triflusal, Disgren, Grendis, Aflen, Triflux )

Catalog No. M14050 CAS No. 322-79-2

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 41 In Stock
5MG 37 In Stock
10MG 49 In Stock
25MG 73 In Stock
50MG 91 In Stock
100MG 126 In Stock
200MG Get Quote In Stock
500MG 230 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Triflusal
  • Note
    Research use only, not for human use.
  • Brief Description
    Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.
  • Description
    Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Triflusal, Disgren, Grendis, Aflen, Triflux
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE| TXA2R
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    322-79-2
  • Formula Weight
    248.16
  • Molecular Formula
    C10H7F3O4
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 50 mg/mL (201.48 mM); DMSO: 50 mg/mL (201.48 mM)
  • SMILES
    O=C(O)C1=CC=C(C(F)(F)F)C=C1OC(C)=O
  • Chemical Name
    2-acetyloxy-4-(trifluoromethyl)benzoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Acta Crystallographica Section A, 49 ( Pt 1), 10-22 (1993)
molnova catalog
related products
  • Apremilast

    Apremilast (CC-10004) is a potent, orally active PDE4 inhibitor with IC50 of 74 nM, inhibits TNF-α production in LPS-stimulated hPBMCs with IC50 of 77 nM.

  • Cilostazol

    Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo.

  • PF-03049423

    PF-03049423 is a potent, selective, orally active, and brain penetrant inhibitor of PDE5 with IC50 of 0.2 nM.